Rchr
J-GLOBAL ID：201901004068540101
Update date: Sep. 11, 2024
sugiyama yosuke
sugiyama yosuke
Affiliation and department：
Research field (1)：
Clinical pharmacy
Research theme for competitive and other funds (2)：
- 2020 - 2023 ウェアラブル活動量計を介したがん性疼痛に対するオピオイド適正モニタリング法の確立
- 2018 - 2020 Construction of scientific opioid rescue dose management system
Papers (39)：
-
Shuzo Hamamoto, Yoshihiko Tasaki, Shimpei Yamashita, Junya Furukawa, Kazutoshi Fujita, Ryotaro Tomida, Makito Miyake, Noriyuki Ito, Hideto Iwamoto, Yosuke Sugiyama, et al. External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal cell carcinoma. Frontiers in Oncology. 2024. 14
-
Teruki Isobe, Taku Naiki, Yosuke Sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Keitaro Iida, Yusuke Noda, Nobuhiko Shimizu, Maria Aoki, et al. Experience and prognostic analysis with avelumab switch maintenance treatment in metastatic urothelial carcinoma. Oncology. 2024
-
Shuzo Hamamoto, Yoshihiko Tasaki, Toshiharu Morikawa, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Shoichiro Iwatsuki, Rei Unno, Tomoki Takeda, Takashi Nagai, et al. Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma. Journal of clinical medicine. 2024. 13. 12
-
Yoshihiko Tasaki, Nanami Ito, Yoshihisa Mimura, Yosuke Sugiyama, Ryo Ogawa, Takaya Shimura, Motoki Nakamura, Daisuke Kawakita, Shuzo Hamamoto, Takehiro Uemura, et al. Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients. Asia-Pacific journal of clinical oncology. 2024
-
Toshiharu Morikawa, Taku Naiki, sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Keitaro Iida, Teruki Isobe, Yusuke Noda, Nobuhiko Shimizu, et al. C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study. Cancers. 2024
ｍore...
MISC (58)：
-
Yoshihiko Tasaki, Shuzo Hamamoto, Taku Naiki, Toshiki Etani, Shoichiro Iwatsuki, Rei Unno, Takashi Nagai, Yoshihisa Mimura, Yosuke Sugiyama, Yuji Hotta, et al. MP10-06 ELEVATED EOSINOPHILS BEFORE 2 COURSE TREATMENT MAY BE A UNIVERSAL BIOMARKER FOR IMMUNE-RELATED ADVERSE EVENTS INDUCED BY COMMON TO DIFFERENT IMMUNE CHECKPOINT INHIBITOR AND CANCER TYPES INCLUDING TO UROLOGICAL CANCER. Journal of Urology. 2024. 211. 5S
-
磯部 輝紀, 内木 拓, 杉山 洋介, 恵谷 俊紀, 清水 伸彦, 権田 将一, 青木 マリア, 森川 敏治, 安藤 亮介, 岡田 淳, et al. 転移性尿路上皮癌に対するアベルマブ治療成績の解析. 日本癌治療学会学術集会抄録集. 2023. 61回. O39-3
-
三村 佳久, 杉山 洋介, 小田切 州広, 田崎 慶彦, 飯田 萌子, 木村 優花, 伊藤 菜浪, 堀田 祐志, 内木 拓, 惠谷 俊紀, et al. Cachexia indexは転移性尿路上皮がん患者の予後予測因子となる. 日本癌治療学会学術集会抄録集. 2023. 61回. O40-1
-
田崎 慶彦, 杉山 洋介, 伊藤 菜浪, 三村 佳久, 飯田 萌子, 小田切 州広, 木村 優花, 堀田 祐志, 内木 拓, 濱本 周造, et al. 好酸球は免疫チェックポイント阻害剤によるirAE発症の予測バイオマーカーとなる. 日本癌治療学会学術集会抄録集. 2023. 61回. MSA O58-3
-
杉山 洋介, 内木 拓, 三村 佳久, 田崎 慶彦, 片岡 智哉, 小田切 州広, 飯田 萌子, 木村 優花, 伊藤 菜浪, 権田 将一, et al. オキシコドンの血中濃度の変化とがん性疼痛との関連性の検討. 日本癌治療学会学術集会抄録集. 2023. 61回. O58-5
ｍore...
Awards (1)：
- 2019/06 - 第24回日本緩和医療学会学術大会 優秀演題賞
Return to Previous Page
